Entrada Therapeutics (TRDA) Accounts Payables (2020 - 2026)

Entrada Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 33.91% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 33.91% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, down 46.25% from the prior year.
• Accounts Payables advanced to $2.9 million in Q1 2026 per TRDA's latest filing, from $2.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $6.5 million in Q1 2023 and bottomed at $752000.0 in Q3 2023.
• The 5-year median for Accounts Payables is $2.5 million (2024), against an average of $2.9 million.
• Across the five-year window, Accounts Payables soared 748.44% in 2022 and slumped 60.97% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $6.0 million in 2022, then slumped by 45.29% to $3.3 million in 2023, then gained by 29.97% to $4.3 million in 2024, then tumbled by 46.25% to $2.3 million in 2025, then increased by 28.0% to $2.9 million in 2026.
• Per Business Quant, the three latest TRDA Accounts Payables figures stand at $2.9 million (Q1 2026), $2.3 million (Q4 2025), and $3.2 million (Q3 2025).